GT Biopharma price target lowered to $8 from $11 at Roth Capital

Roth Capital lowered the firm’s price target on GT Biopharma (GTBP) to $8 from $11 and keeps a Buy rating on the shares. GT Biopharma closed Q3 with $2.6M in cash, sufficient to fund operations into 1Q26, the analyst tells investors in a research note. The company is advancing a Phase 1 trial of second-generation TriKE GTB-3650 in relapsed/refractory CD33+ hematologic malignancies, with initial data expected in 1Q26, and has resumed preclinical development of GTB-5550 for B7H3+ solid tumors, targeting an IND submission by YE25/1Q26.